Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
821 participants
OBSERVATIONAL
2020-10-01
2023-05-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
CArdioMetabolism and Atherosclerotic PlaqUe progreSsion
NCT05117424
Cohort Study in Fujian Province
NCT06102187
Gut Microbiomes in Patients With Metabolic Syndrome
NCT03489317
Gut Microbiota in Chronic Noncommunicable Diseases
NCT04820556
Cardiovascular Diseases and Diabetes Prevention Programme in Metabolic Syndrome (CDPP)
NCT05105321
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Stable angina (SA)
Typical chronic exersive angina pectoris attacks, lasting several minutes to more than 10 minutes, 3-5 minutes in most cases, generally not more than 30 minutes. The pain disappeared after rest or taking nitrates, and the pain degree, frequency, duration, nature and inducing factors did not change in the last 1-3 months.
treatments according guidelines
different group intervened with different treatment following guidelines/consensuses accordingly
Unstable angina (UA）
Including resting angina (attack at rest, the duration is usually \>20 minutes), primary angina (usually the first symptoms within 1-2 months, very light physical activity can be induced, at least CCSIII level), worsening angina (angina gradually increases on the basis of relatively stable labor angina. More severe pain, longer or more frequent pain, at least grade I increase according to THE CCS classification, at least GRADE II CCSI). TNI was negative, routine electrocardiogram may have transient ST segment depression, T wave low flat or inverted.
treatments according guidelines
different group intervened with different treatment following guidelines/consensuses accordingly
Acute non-ST-segment elevation myocardial infarction （NSTEMI）
Patients with elevated troponin accompanied by one or more of the following conditions: electrocardiogram showed new ST segment depression or T wave flatness or inversion; Persistent ischemic chest pain; Echocardiography showed abnormal segmental ventricular wall activity. Abnormal coronary angiography.
treatments according guidelines
different group intervened with different treatment following guidelines/consensuses accordingly
Acute ST-segment elevation myocardial infarction （STEMI）
Troponin was elevated, and ECG showed ST segment arcuate back elevation, accompanied by one or more of the following conditions: persistent ischemic chest pain; Echocardiography showed segmental abnormal ventricular wall activity; Abnormal coronary angiography.
treatments according guidelines
different group intervened with different treatment following guidelines/consensuses accordingly
normal coronary artery （NCA）
symptoms of chest pain and no stenosis in coronary arteries (such as myocardial bridging, reflux esophagitis, intercostals neuralgia, cervical spondylopathy, and unexplained chest pain)
treatments according guidelines
different group intervened with different treatment following guidelines/consensuses accordingly
nonobstructive coronary atherosclerosis （NOCA）
stenosis \< 50% in coronary arteries
treatments according guidelines
different group intervened with different treatment following guidelines/consensuses accordingly
healthy volunteers
Healthy control subjects who had no significant systemic diseases (e.g. ischemic heart disease, hypertension,diabetes,cancer, pulmonary disease, or infectious diseases) were recruited from Physical Examination Center of Ningxia Medical University General Hospital
No interventions assigned to this group
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
treatments according guidelines
different group intervened with different treatment following guidelines/consensuses accordingly
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Or angina pectoris symptoms
* Or ECG ischemic changes
* Or elevated myocardial enzymes, myocardial radionuclide scanning showing myocardial filling defect, coronary CT showing coronary stenosis ≥ 50%
Exclusion Criteria
* Aortic dissection
* Pulmonary embolism
* Malignant tumor
* Autoimmune diseases
* Systemic systemic diseases
* Severe infectious diseases
* Trauma, surgery in the last three months
* Myocarditis, cardiomyopathy, pericarditis, severe congenital heart disease
* Syphilis
* Human immunodeficiency virus / acquired immunodeficiency syndrome
* Hepatitis B and hepatitis C
18 Years
79 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
General Hospital of Ningxia Medical University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Jun He
vice director of the department of cardiovascular internal medicine
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Hechun Xia, MA
Role: STUDY_CHAIR
General Hospital of Ningxia Medical University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Department of Cardiovascular Internal Disease, Guyuan People's Hospital of Ningxia Autonomous Region
Guyuan, Ningxia, China
Fifth People's Hospital of Ningxia Autonomous Region
Shizuishan, Ningxia, China
Affiliated Cardio-Cerebrovascular Hospital of Ningxia Medical University
Yinchuan, Ningxia, China
People's Hospital of Ningxia Hui Autonomous Region
Yinchuan, Ningxia, China
Department of Cardiaovascular Internal Disease, General Hospital of Ningxia Medical University
Yinchuan, Ningxia, China
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Yanning Zhang, M.A
Role: primary
Fuqing Ma, M.A
Role: primary
Fang Liu, M.A
Role: primary
Shaojing Xi, M.A
Role: primary
References
Explore related publications, articles, or registry entries linked to this study.
Iida M, Harada S, Takebayashi T. Application of Metabolomics to Epidemiological Studies of Atherosclerosis and Cardiovascular Disease. J Atheroscler Thromb. 2019 Sep 1;26(9):747-757. doi: 10.5551/jat.RV17036. Epub 2019 Aug 2.
Vaarhorst AA, Verhoeven A, Weller CM, Bohringer S, Goraler S, Meissner A, Deelder AM, Henneman P, Gorgels AP, van den Brandt PA, Schouten LJ, van Greevenbroek MM, Merry AH, Verschuren WM, van den Maagdenberg AM, van Dijk KW, Isaacs A, Boomsma D, Oostra BA, van Duijn CM, Jukema JW, Boer JM, Feskens E, Heijmans BT, Slagboom PE. A metabolomic profile is associated with the risk of incident coronary heart disease. Am Heart J. 2014 Jul;168(1):45-52.e7. doi: 10.1016/j.ahj.2014.01.019. Epub 2014 Apr 4.
Cavus E, Karakas M, Ojeda FM, Kontto J, Veronesi G, Ferrario MM, Linneberg A, Jorgensen T, Meisinger C, Thorand B, Iacoviello L, Bornigen D, Woodward M, Schnabel R, Costanzo S, Tunstall-Pedoe H, Koenig W, Kuulasmaa K, Salomaa V, Blankenberg S, Zeller T; BiomarCaRE consortium. Association of Circulating Metabolites With Risk of Coronary Heart Disease in a European Population: Results From the Biomarkers for Cardiovascular Risk Assessment in Europe (BiomarCaRE) Consortium. JAMA Cardiol. 2019 Dec 1;4(12):1270-1279. doi: 10.1001/jamacardio.2019.4130.
McGarrah RW, Crown SB, Zhang GF, Shah SH, Newgard CB. Cardiovascular Metabolomics. Circ Res. 2018 Apr 27;122(9):1238-1258. doi: 10.1161/CIRCRESAHA.117.311002.
Fan Y, Li Y, Chen Y, Zhao YJ, Liu LW, Li J, Wang SL, Alolga RN, Yin Y, Wang XM, Zhao DS, Shen JH, Meng FQ, Zhou X, Xu H, He GP, Lai MD, Li P, Zhu W, Qi LW. Comprehensive Metabolomic Characterization of Coronary Artery Diseases. J Am Coll Cardiol. 2016 Sep 20;68(12):1281-93. doi: 10.1016/j.jacc.2016.06.044.
Hilvo M, Meikle PJ, Pedersen ER, Tell GS, Dhar I, Brenner H, Schottker B, Laaperi M, Kauhanen D, Koistinen KM, Jylha A, Huynh K, Mellett NA, Tonkin AM, Sullivan DR, Simes J, Nestel P, Koenig W, Rothenbacher D, Nygard O, Laaksonen R. Development and validation of a ceramide- and phospholipid-based cardiovascular risk estimation score for coronary artery disease patients. Eur Heart J. 2020 Jan 14;41(3):371-380. doi: 10.1093/eurheartj/ehz387.
Qin M, Zhu Q, Lai W, Ma Q, Liu C, Chen X, Zhang Y, Wang Z, Chen H, Yan H, Lei H, Zhang S, Dong X, Wang H, Huang M, Lian Q, Zhong S. Insights into the prognosis of lipidomic dysregulation for death risk in patients with coronary artery disease. Clin Transl Med. 2020 Sep;10(5):e189. doi: 10.1002/ctm2.189.
Zhang L, Wei TT, Li Y, Li J, Fan Y, Huang FQ, Cai YY, Ma G, Liu JF, Chen QQ, Wang SL, Li H, Alolga RN, Liu B, Zhao DS, Shen JH, Wang XM, Zhu W, Li P, Qi LW. Functional Metabolomics Characterizes a Key Role for N-Acetylneuraminic Acid in Coronary Artery Diseases. Circulation. 2018 Mar 27;137(13):1374-1390. doi: 10.1161/CIRCULATIONAHA.117.031139. Epub 2017 Dec 6.
Related Links
Access external resources that provide additional context or updates about the study.
Application of Metabolomics to Epidemiological Studies of Atherosclerosis and Cardiovascular Disease
A metabolomic profile is associated with the risk of incident coronary heart disease
Association of Circulating Metabolites With Risk of Coronary Heart Disease in a European Population Results From the Biomarkers for Cardiovascular Risk Assessment in Europe (BiomarCaRE) Consortium
Cardiovascular Metabolomics
ComprehensiveMetabolomicCharacterization of Coronary Artery Diseases
Development and validation of a ceramide- and phospholipid-based cardiovascular risk estimation score for coronary artery disease patients
Insights into the prognosis of lipidomic dysregulation for death risk in patients with coronary artery disease.
Functional Metabolomics Characterizes a Key Role for N-Acetylneuraminic Acid in Coronary Artery Diseases
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
JH
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.